Lindsay Mccaw

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.

Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.

Journal: Cancer medicine
Published: November 30, 2018

Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.

Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.

Journal: Leukemia
Published: July 12, 2018

Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro.

Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro.

Journal: Leukemia research
Published: October 09, 2017

Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.

Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.

Journal: Oncotarget
Published: August 08, 2016

Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells.

Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells.

Journal: EBioMedicine
Published: March 16, 2016

Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

Journal: Haematologica
Published: January 29, 2016

Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.

Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.

Journal: Blood
Published: December 20, 2014

Resveratrol has anti-leukemic activity associated with decreased O-GlcNAcylated proteins.

Resveratrol has anti-leukemic activity associated with decreased O-GlcNAcylated proteins.

Journal: Experimental hematology
Published: March 27, 2013

PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia.

PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia.

Journal: Leukemia
Published: November 20, 2012
Showing 1-9 of 9

Last Updated: 09/26/2026